Clinical Trials

60 enrolled

Prostatic Neoplasms

NCT02123758 2026-04-13

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT03431350 2026-04-13

QUEST

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 3 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04577833 2026-04-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04662580 2026-04-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT03419234 2026-04-01

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

223 enrolled 14 charts

Prostatic Neoplasms

NCT04493853 2026-04-01

CAPItello-281

1,012 enrolled

Prostatic Neoplasms

NCT03436654 2026-03-27

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

102 enrolled

Prostatic Neoplasms

NCT06421935 2026-03-24

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

141 enrolled

Gynecologic

Ovarian Neoplasms

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

196 enrolled

Prostatic Neoplasms

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

21 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

100 enrolled

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

310 enrolled

Prostatic Neoplasms

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

12 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03902951 2026-02-05

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

28 enrolled

Prostatic Neoplasms

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

895 enrolled 19 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT04267887 2026-01-20

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

7 enrolled

Prostatic Neoplasms

NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

90 enrolled

Stage II Prostate Adenocarcinoma

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05367440 2025-12-08

PETRANHA

174 enrolled

Phase EARLY_PHASE1 Active not recruiting

Prostatic Neoplasms

NCT02415621 2025-12-04

Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer

19 enrolled

Phase EARLY_PHASE1 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT03511196 2025-12-04

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

17 enrolled

Prostatic Neoplasms

NCT03012321 2025-10-21

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

70 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT04194554 2025-06-04

ASCLEPIuS

102 enrolled

Prostatic Neoplasms

NCT02913196 2025-05-23

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

16 enrolled

Phase 2/3 Active not recruiting

Prostate Cancer Metastatic

NCT03706365 2025-04-20

CYCLONE 2

393 enrolled 23 charts

Prostatic Neoplasms

NCT04691804 2024-12-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

496 enrolled

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT02807805 2024-12-18

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

37 enrolled

Prostatic Neoplasms

NCT01957436 2024-11-12

PEACE1

1,173 enrolled

Neoplasms, Prostatic Neoplasms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

345 enrolled

Prostatic Neoplasms

NCT06193993 2024-01-08

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

10 enrolled

Phase 2/3 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT00268476 2023-04-18

STAMPEDE

11,992 enrolled